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Article
Motor function measure scale, steroid therapy 
and patients with Duchenne muscular 
dystrophy
Medida de função motora, corticoterapia e pacientes com distrofia muscular de Duchenne
Elaine C. da Silva1, Darlene L. Machado1, Maria B. D. Resende1, Renata F. Silva1, Edmar Zanoteli2,  
Umbertina C. Reed1
Duchenne muscular dystrophy (DMD) is the most com-
mon and severe muscular dystrophy, affecting about 1:3500 
live male births1 and causing loss of the ability to walk inde-
pendently by 10 to 12 years of age. Its treatment remains palli-
ative and relies mainly on steroids and physiotherapy, both in 
order to slow the loss of motor function2-4. Several tests have 
been reported in the literature to assess muscle strength and 
functional ability, to monitor the progression of the disease, 
and to evaluate the results of drug interventions and rehabil-
itation4-12. However, most instruments involve ambulant pa-
tients, making adjustments and/or additional assessments 
necessary when the disease progresses8,9. The Motor Function 
Measure (MFM), which was an assessment tool to measure 
motor function in patients with neuromuscular disorders, 
was developed13 in 2005, in France, and it was later validat-
ed in Brazil14. It includes 32 items that evaluate three dimen-
sions of motor performance, including specific motor func-
tions, such as transfers and standing posture (D1), proximal 
and axial (D2), distal (D3) and a total MFM score involving all 
of the motor dimensions. The items are scored and summed 
to comprise a total score, in which the maximum represents 
normal motor function. 
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AbstrAct
Objective: To assess the evolution of motor function in patients with Duchenne muscular dystrophy (DMD) treated with steroids (predni-
solone or deflazacort) through the Motor Function Measure (MFM), which evaluates three dimensions of motor performance (D1, D2, D3). 
Methods: Thirty-three patients with DMD (22 ambulant, 6 non-ambulant and 5 who lost the capacity to walk during the period of the study) 
were assessed using the MFM scale six times over a period of 18 months. Results: All the motor functions remained stable for 14 months in 
all patients, except D1 for those who lost their walking ability. In ambulant patients, D2 (axial and proximal motor capacities) motor functions 
improved during six months; an improvement in D3 (distal motor capacity) was noted during the total follow-up. D1 (standing posture and 
transfers) and total score were useful to predict the loss of the ability to walk. Conclusions: The use of the MFM in DMD patients confirms the 
benefits of the steroid treatment for slowing the progression of the disease.
Key words: motor function measure, muscular dystrophy, Duchenne, neuromuscular disease.
resuMo
Objetivo: Avaliar a evolução da função motora de pacientes com distrofia muscular de Duchenne (DMD) em corticoterapia (predinisolona 
e deflazacort), por meio da escala Medida da Função Motora (MFM), que avalia três dimensões de funções motoras (D1, D2, D3). Métodos: 
Trinta e três pacientes com DMD (22 deambulantes, seis cadeirantes e cinco que perderam a capacidade de andar ao longo do estudo) foram 
avaliados pela escala MFM em seis momentos durante 18 meses. Resultados: Todas as funções motoras mantiveram-se estáveis durante 
14 meses, exceto D1 para os pacientes que perderam a marcha. Nos pacientes deambulantes, a D2 (função motora axial e proximal) apre-
sentou melhora durante seis meses. Melhora em D3 (função motora distal) também foi observada durante o seguimento. A D1 (postura em 
pé e transferências) e o escore total foram importantes para predizer a perda de marcha. Conclusões: O uso da MFM nos pacientes com DMD 
confirma os benefícios do tratamento com corticoides na diminuição da velocidade de progressão da doença.
Palavras-Chave: medida da função motora, distrofia muscular de Duchenne, doença neuromuscular.
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Using this tool, longitudinal studies to assess motor func-
tion are possible in both ambulant and wheelchair patients. 
The purpose of this study was to verify the evolution of mo-
tor function with this new assessment tool in patients with 
DMD, who were on steroid therapy.
MetHoDs
The study included 44 patients (ambulant and non-am-
bulant) with DMD, aged six to 16 years-old. The DMD diagno-
sis was confirmed by molecular analysis and/or immunohis-
tochemistry and Western blot for dystrophin in muscle biopsy, 
and all patients were submitted to laboratory tests before the 
onset of steroid therapy utilizing two possible schemes: pred-
nisolone (0.75 mg/kg per day intermittently ten days on and 
ten days off) for those children less than seven years-old, or 
deflazacort (0.9 mg/kg/day) daily for the older ones.
All patients were able to actively collaborate in the motor 
tasks of the MFM. An initial assessment was made to collect 
general information, including the date of loss of ambulation 
and the type and weekly frequency of attendance at physi-
cal therapy center. When patients did not attend any type of 
physical therapy (hydrotherapy and conventional physical 
therapy), they were counseled and referred to specialized re-
habilitation care centers. As those treatments were not car-
ried out at the same rehabilitation center, all caregivers were 
explained about how doing some traditionally physical exer-
cises at home. After having obtained the authors’ authoriza-
tion, we applied the MFM and registered the aspects of mo-
tor function (D1, D2, D3) and the total MFM score, according 
to materials and methods described in the instruction man-
ual, which can be found at: http://www.mfm.nmd.ord. Each 
patient was evaluated six times by the same physical thera-
pist on the day of the patient’s medical appointment for 18 
months. The first visit preceded the onset of steroid therapy. 
The interval between the first and second visits and between 
the second and third visits was three months. The interval 
between the remaining successive visits was four months. 
Evaluations were performed before each appointment. The 
term of consent was signed by the patients/parents and it was 
previously approved by the Ethics Committee for Analysis of 
Research Projects of the Department of Neurology, Medical 
School of the University of São Paulo, São Paulo SP, Brazil). 
Statistical analysis was performed using ANOVA for repeated 
measures, followed by Tukey’s range test. In each statistical 
analysis, a significance level of 5% (p<0.05) was adopted.
results
Forty-four patients with DMD, who were on steroid ther-
apy, were followed. Of these patients, 11 did not complete 
the study (seven did not regularly attend the assessments, 
two dropped out of the follow-up study, one did not regularly 
maintain medication, and one died). Thus, 33 patients com-
pleted the study. Of these patients, 22 (66.7%) were ambulant, 
six (18.2%) were non-ambulant, and five (15.1%) lost walking 
capacity during the study (Table 1). 
D1 was not analyzed in the group of non-ambulant pa-
tients, because it measures motor function associated with 
the standing position and transfer from one place to another. 
In ambulant patients, D1 and the total score remained sta-
ble for 10 to 14 months after starting the treatment (Table 2). 
There was a marked improvement in D2 motor function in 
the first six months of treatment, with some time of stability 
throughout the follow-up period. There was functional gain 
in D3 during the entire follow-up period (Table 2).
In non-ambulant patients, we observed maintenance of 
D2 and total score during the follow-up period with func-
tional loss during the last visits for D2, except for D3 mea-
surement, which remained stable throughout the follow-up 
period (Table 3). In the group of patients who lost walking 
ability during the follow-up period, D1 began to decline after 
Table 1. General data of 33 steroid-treated patients with 
Duchenne muscular dystrophy.
Patients Age (mean/minimum-maximum)
Age at loss of 
walking capacity
Ambulant
n=22 (66.7%)
7.6 (6–10) 
±1.2
–
Loss of walking 
capacity
n= 5 (15.1%)
10 (9–11) 
±0.7
10.4 (9–12) 
±1.1
Non-ambulant
n=6 (18.2%)
12.5 (8–16)
±3.1
–
Table 2. Comparison of mean percentages of motor functional measure scores on the first evaluation (V0) with each subsequent 
visit (V1, V2, V3, V4 and V5) in the group of 22 ambulant patients with Duchenne muscular dystrophy.
Motor function V0 (%)baseline
V1 (%)
3mo
V2 (%)
6mo
V3 (%)
10mo
V4 (%)
14mo
V5 (%)
18mo
D1 69.5±2.9 71.0±4.0 69.2±14.0 65.6±13.4 61.7±13.1*** 57.7±12.4***
D2 93±5.0 94.8±3.86 95.7±2.7** 94.9±2.8 93.3±2.8 91.8±3.6
D3 84.3±8.5 87.9±5.6* 87.2±6.2* 90.0±5.9* 90.5±7*** 88.8±6.6**
Total 81.6±7.2 83.5±7.3 83.2±6.2 81.8±6.7 79.7±6.1 77.3±6.1***
D1: standing and transfers capacities; D2: axial and proximal motor capacities; D3: distal motor capacity; Total: total score; mo: months; *p<0.05; **p<0.01; 
***p<0.001.
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the third visit, D2 and the total score began to decline during 
the final visits, and D3 remained constant during the follow-
up period (Table 4). With the exception of the two patients 
who lost their walking ability at the second visit, one patient 
lost his/her walking ability at the third visit and two patients 
lost their walking ability at the forth one. The mean scores 
at the time that walking ability was lost in those patients 
were: D1=22.51% (±4.97%), D2=92.22% (±1.24%), D3=91.43% 
(±3.99%), and total score =63.12% (±2.03%). 
DiscussioN
Because the MFM displays losses and gains at each stage 
of the disease and for each motor function, the MFM is an 
excellent method of evaluating DMD patients on steroid 
therapy or other new therapeutic strategies. Our aim was to 
demonstrate the advantages for the use of MFM as a tool for 
monitoring the functional outcome of patients with DMD on 
steroid therapy; the purpose was not to evaluate the benefi-
cial effects of medication on disease progression, which have 
been well recognized during the last two decades2,15-20.
In previous studies, several methods have been used to 
assess and monitor motor function in patients on steroid 
therapy3,9,11,12, and the search for the ideal instrument remains 
an objective in several centers for neuromuscular diseases9,21. 
The MFM has been applied successfully in some studies of 
treated DMD patients13,14,22. Recently, Vuillerot et al.23 com-
pared 12 steroid-treated patients with a Control Group of 12 
untreated patients over a 12-month period; patients treat-
ed with steroids had more stable total MFM scores and D2 
sub-scores, confirming the beneficial use of steroids for pa-
tients with DMD. Although muscle strength was not evalu-
ated in our study, a recent report has compared the scores 
obtained with the Medical Research Council (MRC) index 
and the MFM23.
Since the items assessed by the MFM permit the evalua-
tion of the course of DMD, during the follow-up, our patients 
were divided into three groups (ambulant patients, non-am-
bulant patients, and those who lost walking ability during the 
study period). The division of patients into these groups and 
the short periods of time between each evaluation allowed a 
better understanding of the application and the effectiveness 
of the MFM. 
In the group of ambulant patients, the MFM was prov-
en to be effective for mapping disease progression in stand-
ing posture and transfer. We noted a period of stability for D1 
followed by functional losses at the end of 18 months. Since 
D1 is related to the ability to walk, our findings were simi-
lar to previous results, which demonstrated that medication 
can extend the walking ability for months to two years2,3,16,18,24. 
Despite the inevitable decline in D1 at the end of the follow-
up period, we found an increase in D2 in the first months of 
medication, and an increase in D3 throughout the follow-up 
period. This resulted in the stabilization of the total score. 
Therefore, the MFM suggests that physical therapeutic ac-
tivities should focus on proximal, axial, and distal muscles 
during this period. For DMD is a progressive disease, the 
maintenance of motor function for months or years can pre-
vent the accumulation of incapacities18. Other authors who 
utilized the MFM found variations in motor functions in the 
short-term (six months)22. However, they suggested that in 
new studies, patients should be monitored for more than six 
months, which is the case in the present study. 
The dimensions assessed by the MFM seem to indicate 
with reasonable precision early motor deficits, as well tran-
sition periods in the course of the disease. The D1 seems to 
be the most informative dimension in ambulant patients, 
Table 3. Comparison of mean percentages of motor functional measure scores on the first evaluation (V0) with each subsequent 
visit (V1, V2, V3, V4 and V5) in the group of six non-ambulant patients with Duchenne muscular dystrophy.
Motor function V0 (%)baseline
V1 (%)
3mo
V2 (%)
6mo
V3 (%)
10mo
V4 (%)
14mo
V5 (%)
18mo
D2 50.9±24.7 55.1±26.3 52.3±25.6 54.2±25.3 46.3±22.5 41.2±22.0**
D3 71.4±17.0 74.6±18.0 74.6±17.7 71.4±25.4 67.5±22.8 64.3±23.7
Total 34.5±13.2 37.8±14.6 37.0±14.6 37.0±16.49 33.0±14.0 30.9±14.9
D2: axial and proximal motor capacities; D3: distal motor capacity; Total: total score; mo: months; *p<0.05; **p<0.01; ***p<0.001.
D1: standing and transfers capacities; D2: axial and proximal motor capacities; D3: distal motor capacity; Total: total score; mo: months; *p<0.05; **p<0.01; 
***p<0.001.
Table 4. Comparison of mean percentages of motor functional measure scores on the first evaluation (V0) and with each 
subsequent visit (V1, V2, V3, V4 and V5) in the group of five patients with Duchenne muscular dystrophy that lost the walk ability.
Motor function V0 (%)baseline
V1 (%)
3mo
V2 (%)
6mo
V3 (%)
10mo
V4 (%)
14mo
V5 (%)
18mo
D1 33.3±9.0 31.3±11.4 22.1±8.0 15.9±9.7** 12.8±6.0*** 7.7±0.0**
D2 91.7±3.9 92.8±3.16 92.8±1.5 91.7±2.0 88.9±3.4 83.3±6.5**
D3 89.±5.2 90.5±4.8 93.3±4.3 92.4±4.3 89.5±4.0 85.7±5.8
Total 66.9±4.2 67.3±6.3 64.2±4.0 60.8±4.2 58.1±4.1 53.1±2.8***
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